Outlook Wealth Advisors’s iShares US Medical Devices ETF IHI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-94,519
Closed -$4.77M 191
2022
Q2
$4.77M Sell
94,519
-7,037
-7% -$384K 1.95% 10
2022
Q1
$6.19M Sell
101,556
-20,063
-16% -$1.2M 2.07% 13
2021
Q4
$8.01M Buy
121,619
+31,151
+34% +$1.99M 2.35% 10
2021
Q3
$5.68M Buy
90,468
+34,446
+61% +$2.2M 1.86% 10
2021
Q2
$3.37M Sell
56,022
-56,514
-50% -$3.27M 1.08% 27
2021
Q1
$6.2M Buy
112,536
+4,734
+4% +$263K 2.15% 7
2020
Q4
$5.88M Buy
107,802
+17,928
+20% +$937K 2.14% 11
2020
Q3
$4.49M Buy
89,874
+7,050
+9% +$341K 1.78% 14
2020
Q2
$3.65M Buy
82,824
+5,682
+7% +$243K 1.55% 16
2020
Q1
$2.9M Sell
77,142
-17,862
-19% -$752K 1.64% 16
2019
Q4
$4.18M Buy
95,004
+25,362
+36% +$1.07M 2.36% 8
2019
Q3
$2.87M Buy
69,642
+15,834
+29% +$648K 1.71% 12
2019
Q2
$2.16M Buy
53,808
+22,566
+72% +$854K 1.42% 14
2019
Q1
$1.21M Buy
+31,242
New +$1.13M 0.99% 24

Other funds holding IHI

Outlook Wealth Advisors's IHI Position: Q3 2022 in Review

Outlook Wealth Advisors sold out of iShares US Medical Devices ETF (IHI) in Q3 2022, closing a stake of 94,519 shares — an estimated $4.77M sold.

Outlook Wealth Advisors first reported a position in IHI in Q1 2019 and held it in 14 quarters. The position peaked at $8.01M in Q4 2021. 556 funds tracked by Wall St. Rank hold IHI as of Q3 2022.

  • Outlook Wealth Advisors reported no remaining iShares US Medical Devices ETF position as of Q3 2022 after selling out during the quarter.
  • Outlook Wealth Advisors sold 94,519 iShares US Medical Devices ETF shares in Q3 2022, an estimated $4.77M.
  • Outlook Wealth Advisors first reported a position in iShares US Medical Devices ETF in Q1 2019 and held it in 14 quarters.
  • Outlook Wealth Advisors's iShares US Medical Devices ETF position peaked at $8.01M in Q4 2021.
  • 556 funds tracked by Wall St. Rank held iShares US Medical Devices ETF as of Q3 2022.

Based on Outlook Wealth Advisors's 13F filing for Q3 2022, filed 25 Oct 2022.